{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T20:18:40Z","timestamp":1790108320895,"version":"4.0.1"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,10,15]],"date-time":"2020-10-15T00:00:00Z","timestamp":1602720000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,10,15]],"date-time":"2020-10-15T00:00:00Z","timestamp":1602720000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100004480","name":"Natural Science Foundation of Shanxi Province","doi-asserted-by":"publisher","award":["201901D111193"],"award-info":[{"award-number":["201901D111193"]}],"id":[{"id":"10.13039\/501100004480","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Shanxi \u201c1331 Project\u201d Key Subjects Construction","award":["XK201708"],"award-info":[{"award-number":["XK201708"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardiovasc Drugs Ther"],"published-print":{"date-parts":[[2021,2]]},"DOI":"10.1007\/s10557-020-07088-5","type":"journal-article","created":{"date-parts":[[2020,10,15]],"date-time":"2020-10-15T06:02:47Z","timestamp":1602741767000},"page":"87-101","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":24,"title":["Glucagon-Like Peptide-1 Analog Liraglutide Attenuates Pressure-Overload Induced Cardiac Hypertrophy and Apoptosis through Activating ATP Sensitive Potassium Channels"],"prefix":"10.1007","volume":"35","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2892-6625","authenticated-orcid":false,"given":"Xiao-Jie","family":"Bai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun-Tao","family":"Hao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rong-Hua","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cai-Ping","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cai-Hong","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei-Fang","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhi-Qing","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,10,15]]},"reference":[{"key":"7088_CR1","doi-asserted-by":"publisher","first-page":"1463","DOI":"10.1002\/cphy.c170048","volume":"8","author":"A Tinker","year":"2018","unstructured":"Tinker A, Aziz Q, Li Y, Specterman M. ATP-sensitive potassium channels and their physiological and pathophysiological roles. Compr Physiol. 2018;8:1463\u2013511.","journal-title":"Compr Physiol"},{"key":"7088_CR2","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1007\/s00210-019-01642-1","volume":"392","author":"K Iguchi","year":"2019","unstructured":"Iguchi K, Saotome M, Yamashita K, et al. Pinacidil, a KATPchannel opener, stimulates cardiac Na(+)\/Ca(2+) exchanger function through the NO\/cGMP\/PKG signaling pathway in Guinea pig cardiac ventricular myocytes. Arch Pharmacol. 2019;392:949\u201359.","journal-title":"Arch Pharmacol"},{"key":"7088_CR3","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.biocel.2015.10.029","volume":"70","author":"S Jovanovi\u0107","year":"2016","unstructured":"Jovanovi\u0107 S, Ballantyne T, Du Q, Blagojevi\u0107 M, Jovanovi\u0107 A. Phenylephrine preconditioning in embryonic heart H9c2 cells is mediated by up-regulation of SUR2B\/Kir6.2: a first evidence for functional role of SUR2B in sarcolemmal KATP channels and cardioprotection. Int J Biochem Cell Biol. 2016;70:23\u20138.","journal-title":"Int J Biochem Cell Biol"},{"key":"7088_CR4","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1161\/01.RES.88.6.570","volume":"88","author":"M Suzuki","year":"2001","unstructured":"Suzuki M, Li RA, Miki T, et al. Functional roles of cardiac and vascular ATP-sensitive potassium channels clarified by Kir6.2-knockout mice. Circ Res. 2001;88:570\u20137.","journal-title":"Circ Res"},{"key":"7088_CR5","doi-asserted-by":"publisher","first-page":"2504","DOI":"10.1249\/MSS.0000000000000714","volume":"47","author":"J Kraljevic","year":"2015","unstructured":"Kraljevic J, H\u00f8ydal MA, Ljubkovic M, et al. Role of KATP channels in beneficial effects of exercise in ischemic heart failure. Med Sci Sports Exerc. 2015;47:2504\u201312.","journal-title":"Med Sci Sports Exerc"},{"key":"7088_CR6","doi-asserted-by":"publisher","first-page":"662","DOI":"10.1002\/cmdc.201700781","volume":"13","author":"JY Cheang","year":"2018","unstructured":"Cheang JY, Moyle PM. Glucagon-like peptide-1 (GLP-1)-based therapeutics: current status and future opportunities beyond type\u00a02 diabetes. ChemMedChem. 2018;13:662\u201371.","journal-title":"ChemMedChem"},{"key":"7088_CR7","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1007\/s40262-015-0343-6","volume":"55","author":"LV Jacobsen","year":"2016","unstructured":"Jacobsen LV, Flint A, Olsen AK, Ingwersen SH. Liraglutide in type 2 diabetes mellitus: clinical pharmacokinetics and pharmacodynamics. Clin Pharmacokinet. 2016;55:657\u201372.","journal-title":"Clin Pharmacokinet"},{"key":"7088_CR8","doi-asserted-by":"publisher","first-page":"954","DOI":"10.1124\/pr.115.011395","volume":"68","author":"DD Graaf Cd","year":"2016","unstructured":"Graaf Cd DD, Wootten D, et al. Glucagon-like peptide-1 and its class B G protein-coupled receptors: a long march to therapeutic successes. Pharmacol Rev. 2016;68:954\u20131013.","journal-title":"Pharmacol Rev"},{"key":"7088_CR9","doi-asserted-by":"publisher","first-page":"952","DOI":"10.1016\/j.biopha.2018.08.088","volume":"108","author":"D Sharma","year":"2018","unstructured":"Sharma D, Verma S, Vaidya S, Kalia K, Tiwari V. Recent updates on GLP-1 agonists: current advancements & challenges. Biomed Pharmacother. 2018;108:952\u201362.","journal-title":"Biomed Pharmacother"},{"key":"7088_CR10","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1016\/j.ijcard.2017.02.126","volume":"241","author":"M Luconi","year":"2017","unstructured":"Luconi M, Cantini G, Ceriello A, Mannucci E. Perspectives on cardiovascular effects of incretin-based drugs: from bedside to bench, return trip. Int J Cardiol. 2017;241:302\u201310.","journal-title":"Int J Cardiol"},{"key":"7088_CR11","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1161\/CIRCULATIONAHA.117.028136","volume":"136","author":"MA Nauck","year":"2017","unstructured":"Nauck MA, Meier JJ, Cavender MA, Abd El Aziz M, Drucker DJ. Cardiovascular actions and clinical outcomes with glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors. Circulation. 2017;136:849\u201370.","journal-title":"Circulation"},{"key":"7088_CR12","doi-asserted-by":"publisher","first-page":"2745","DOI":"10.2147\/DDDT.S213910","volume":"13","author":"RH Zheng","year":"2019","unstructured":"Zheng RH, Bai XJ, Zhang WW, et al. Liraglutide attenuates cardiac remodeling and improves heart function after abdominal aortic constriction through blocking angiotensin II type 1 receptor in rats. Drug Des Devel Ther. 2019;13:2745\u201357.","journal-title":"Drug Des Devel Ther"},{"key":"7088_CR13","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/j.ceca.2017.09.002","volume":"67","author":"Y Olgar","year":"2017","unstructured":"Olgar Y, Celen MC, Yamasan BE, Ozturk N, Turan B, Ozdemir S. Rho-kinase inhibition reverses impaired Ca2+ handling and associated left ventricular dysfunction in pressure overload-induced cardiac hypertrophy. Cell Calcium. 2017;67:81\u201390.","journal-title":"Cell Calcium"},{"key":"7088_CR14","doi-asserted-by":"publisher","first-page":"H1508","DOI":"10.1152\/ajpheart.00540.2013","volume":"305","author":"NM Storey","year":"2013","unstructured":"Storey NM, Stratton RC, Rainbow RD, Standen NB, Lodwick D. Kir6.2 limits Ca(2+) overload and mitochondrial oscillations of ventricular myocytes in response to metabolic stress. Am J Physiol Heart Circ Physiol. 2013;305:H1508\u201318.","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"7088_CR15","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1016\/j.bbrc.2015.11.127","volume":"469","author":"HJ Kwon","year":"2016","unstructured":"Kwon HJ, Park HS, Park SH, et al. Evidence for glucagon-like peptide-1 receptor signaling to activate ATP-sensitive potassium channels in pancreatic beta cells. Biochem Biophys Res Commun. 2016;469:216\u201321.","journal-title":"Biochem Biophys Res Commun"},{"key":"7088_CR16","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1007\/s10557-015-6592-7","volume":"29","author":"LH Zhang","year":"2015","unstructured":"Zhang LH, Pang XF, Bai F, et al. Preservation of glucagon-like peptide-1 level attenuates angiotensin II-induced tissue fibrosis by altering AT1\/AT2 receptor expression and angiotensin-converting enzyme 2 activity in rat heart. Cardiovasc Drugs Ther. 2015;29:243\u201355.","journal-title":"Cardiovasc Drugs Ther"},{"key":"7088_CR17","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1111\/fcp.12529","volume":"34","author":"MMM Refaie","year":"2020","unstructured":"Refaie MMM, Rifaai RA, Bayoumi AMA, Shehata S. Cardioprotective effect of hemin in isoprenaline-induced myocardial infarction: role of ATP-sensitive potassium channel and endothelial nitric oxidesynthase. Fundam Clin Pharmacol. 2020;34:302\u201312.","journal-title":"Fundam Clin Pharmacol"},{"key":"7088_CR18","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1472-6793-5-1","volume":"5","author":"A Morrissey","year":"2005","unstructured":"Morrissey A, Rosner E, Lanning J, et al. Immunolocalization of KATP channel subunits in mouse and rat cardiac myocytes and the coronary vasculature. BMC Physiol. 2005;5:1\u201310.","journal-title":"BMC Physiol"},{"key":"7088_CR19","doi-asserted-by":"publisher","first-page":"8123","DOI":"10.3892\/mmr.2017.7640","volume":"16","author":"FC Tang","year":"2017","unstructured":"Tang FC, Wang HY, Ma MM, et al. Simvastatin attenuated rat thoracic aorta remodeling by decreasing ROCK2-mediated CyPA secretion and CD147-ERK1\/2-cyclin pathway. Mol Med Rep. 2017;16:8123\u20139.","journal-title":"Mol Med Rep"},{"key":"7088_CR20","doi-asserted-by":"crossref","unstructured":"Ni X, Wong SL, Wong CM, et al. Tetramethylpyrazine protects against hydrogen peroxide-provoked endothelial dysfunction in isolated rat aortic rings: implications for antioxidant therapy of vascular diseases. Evid Based Complement Alternat Med 2014; 2014:627181.","DOI":"10.1155\/2014\/627181"},{"key":"7088_CR21","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1186\/1475-2840-12-75","volume":"12","author":"ZW Yang","year":"2013","unstructured":"Yang ZW, Chen JK, Ni M, et al. Role of Kir6.2 subunits of ATP-sensitive potassium channels in endotoxemia-induced cardiac dysfunction. Cardiovasc Diabetol. 2013;12:75\u201385.","journal-title":"Cardiovasc Diabetol"},{"key":"7088_CR22","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1097\/00000542-200402000-00024","volume":"100","author":"T Kawano","year":"2004","unstructured":"Kawano T, Oshita S, Takahashi A, et al. Molecular mechanisms of the inhibitory effects of propofol and thiamylal on sarcolemmal adenosine triphosphate-sensitive potassium channels. Anesthesiology. 2004;100:338\u201346.","journal-title":"Anesthesiology"},{"key":"7088_CR23","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1111\/bph.12407","volume":"171","author":"A Tinker","year":"2014","unstructured":"Tinker A, Aziz Q, Thomas A. The role of ATP-sensitive potassium channels in cellular function and protection in the cardiovascular system. Br J Pharmacol. 2014;171:12\u201323.","journal-title":"Br J Pharmacol"},{"key":"7088_CR24","doi-asserted-by":"publisher","first-page":"H262","DOI":"10.1152\/ajpheart.00857.2010","volume":"300","author":"L Bao","year":"2011","unstructured":"Bao L, Hadjiolova K, Coetzee WA, Rindler MJ. Endosomal KATPchannels as a reservoir after myocardial ischemia: a role for SUR2 subunits. Am J Physiol Heart Circ Physiol. 2011;300:H262\u201370.","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"7088_CR25","doi-asserted-by":"publisher","first-page":"1046","DOI":"10.1096\/fj.04-1602fje","volume":"18","author":"GR Budas","year":"2004","unstructured":"Budas GR, Jovanovic S, Crawford RM, Jovanovic A. Hypoxia-induced preconditioning in adult stimulated cardiomyocytes is mediated by the opening and trafficking of sarcolemmal KATP channels. FASEB J. 2004;18:1046\u20138.","journal-title":"FASEB J"},{"key":"7088_CR26","doi-asserted-by":"publisher","first-page":"H1100","DOI":"10.1152\/ajpheart.00084.2010","volume":"299","author":"DA Stoller","year":"2010","unstructured":"Stoller DA, Fahrenbach JP, Chalupsky K, et al. Cardiomyocyte sulfonylurea receptor 2-KATP channel mediates cardioprotection and ST segment elevation. Am J Physiol Heart Circ Physiol. 2010;299:H1100\u20138.","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"7088_CR27","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1172\/JCI0215672","volume":"110","author":"WA Chutkow","year":"2002","unstructured":"Chutkow WA, Jielin P, Wheeler MT, et al. Episodic coronary artery vasospasm and hypertension develop in the absence of Sur2 KATP channels. J Clin Invest. 2002;110:203\u20138.","journal-title":"J Clin Invest"},{"key":"7088_CR28","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1016\/S0008-6363(02)00504-7","volume":"56","author":"AJ Wilson","year":"2002","unstructured":"Wilson AJ, Clapp LH. The molecular site of action of K(ATP) channel inhibitors determines their ability to inhibit iNOS-mediated relaxation in rat aorta. Cardiovasc Res. 2002;56:154\u201363.","journal-title":"Cardiovasc Res"},{"key":"7088_CR29","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1016\/j.pharmthera.2010.04.005","volume":"128","author":"BC Bernardo","year":"2010","unstructured":"Bernardo BC, Weeks KL, Pretorius L, McMullen JR. Molecular distinction between physiological and pathological cardiac hypertrophy: experimental findings and therapeutic strategies. Pharmacol Ther. 2010;128:191\u2013227.","journal-title":"Pharmacol Ther"},{"key":"7088_CR30","doi-asserted-by":"publisher","first-page":"1765","DOI":"10.1152\/physrev.00022.2018","volume":"99","author":"DP Del Re","year":"2019","unstructured":"Del Re DP, Amgalan D, Linkermann A, Liu Q, Kitsis RN. Fundamental mechanisms of regulated cell death and implications for heart disease. Physiol Rev. 2019;99:1765\u2013817.","journal-title":"Physiol Rev"},{"key":"7088_CR31","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1016\/j.biopha.2018.06.129","volume":"106","author":"T Xu","year":"2018","unstructured":"Xu T, Lv Z, Chen Q, Guo M, Wang X, Huang F. Vascular endothelial growth factor over-expressed mesenchymal stem cells-conditioned media ameliorate palmitate-induced diabetic endothelial dysfunction through PI-3K\/AKT\/m-TOR\/eNOS and p38\/MAPK signaling pathway. Biomed Pharmacother. 2018;106:491\u20138.","journal-title":"Biomed Pharmacother"},{"key":"7088_CR32","doi-asserted-by":"publisher","first-page":"2493","DOI":"10.1016\/j.bbrc.2018.07.005","volume":"503","author":"MY Ho","year":"2018","unstructured":"Ho MY, Wen MS, Yeh JK, et al. Excessive irisin increases oxidative stress and apoptosis in murine heart. Biochem Biophys Res Commun. 2018;503:2493\u20138.","journal-title":"Biochem Biophys Res Commun"},{"key":"7088_CR33","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1177\/1074248417729880","volume":"23","author":"K Jeevaratnam","year":"2018","unstructured":"Jeevaratnam K, Chadda KR, Huang CL, Camm AJ. Cardiac potassium channels: physiological insights for targeted therapy. J Cardiovasc Pharmacol Ther. 2018;23:119\u201329.","journal-title":"J Cardiovasc Pharmacol Ther"},{"key":"7088_CR34","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1124\/jpet.104.074369","volume":"312","author":"SY Lee","year":"2005","unstructured":"Lee SY, Lee CO. Inhibition of Na+-K+ pump and L-type Ca2+ channel by Glibenclamide in Guinea pig ventricular myocytes. JPET. 2005;312:61\u20138.","journal-title":"JPET"},{"key":"7088_CR35","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1007\/s12272-001-1182-9","volume":"31","author":"SH Lee","year":"2008","unstructured":"Lee SH, Yang MK, Lim JH, et al. KR-31762, a novel KATP channel opener, exerts cardioprotective effects by opening SarcKATP channels in rat models of ischemia\/ reperfusion -induced heart injury. Arch Pharm Res. 2008;31:482\u20139.","journal-title":"Arch Pharm Res"},{"key":"7088_CR36","doi-asserted-by":"publisher","first-page":"574","DOI":"10.1038\/s41419-020-02777-3","volume":"11","author":"JY Wang","year":"2020","unstructured":"Wang JY, Deng B, Liu Q, et al. Pyroptosis and ferroptosis induced by mixed lineage kinase 3 (MLK3) signaling in cardiomyocytes are essential for myocardial fibrosis in response to pressure overload. Cell Death Dis. 2020;11:574.","journal-title":"Cell Death Dis"},{"key":"7088_CR37","doi-asserted-by":"publisher","first-page":"172715","DOI":"10.1016\/j.ejphar.2019.172715","volume":"864","author":"XY Yu","year":"2019","unstructured":"Yu XY, Hao M, Yu Liu Y, et al. Liraglutide ameliorates non-alcoholic steatohepatitis by inhibiting NLRP3 inflammasome and pyroptosis activation via mitophagy. Eur J Pharmacol. 2019;864:172715.","journal-title":"Eur J Pharmacol"},{"key":"7088_CR38","doi-asserted-by":"publisher","first-page":"1340","DOI":"10.1111\/j.1476-5381.2009.00376.x","volume":"157","author":"DJ Grieve","year":"2009","unstructured":"Grieve DJ, Cassidy RS, Green BD. Emerging cardiovascular actions of the incretin hormone glucagon-like peptide-1: potential therapeutic benefits beyond glycaemic control? Br J Pharmacol. 2009;157:1340\u201351.","journal-title":"Br J Pharmacol"},{"key":"7088_CR39","doi-asserted-by":"publisher","first-page":"1128","DOI":"10.1016\/j.jacc.2019.12.063","volume":"75","author":"SP Marso","year":"2020","unstructured":"Marso SP, Baeres FMM, Bain SC, et al. Effects of liraglutide on cardiovascular outcomes in patients with diabetes with or without Heart Failure. J Am CollCardiol. 2020;75:1128\u201341.","journal-title":"J Am CollCardiol"},{"key":"7088_CR40","doi-asserted-by":"publisher","first-page":"154045","DOI":"10.1016\/j.metabol.2019.154045","volume":"104","author":"F Giorgino","year":"2020","unstructured":"Giorgino F, Caruso I, Moellmann J, Lehrke M. Differential indication for SGLT-2 inhibitors versus GLP-1 receptor agonists in patients with established atherosclerotic heart disease or at risk for congestive heart failure. Metabolism. 2020;104:154045.","journal-title":"Metabolism."}],"container-title":["Cardiovascular Drugs and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10557-020-07088-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10557-020-07088-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10557-020-07088-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,10,15]],"date-time":"2021-10-15T07:49:49Z","timestamp":1634284189000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10557-020-07088-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10,15]]},"references-count":40,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,2]]}},"alternative-id":["7088"],"URL":"https:\/\/doi.org\/10.1007\/s10557-020-07088-5","relation":{},"ISSN":["0920-3206","1573-7241"],"issn-type":[{"value":"0920-3206","type":"print"},{"value":"1573-7241","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,10,15]]},"assertion":[{"value":"22 September 2020","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 October 2020","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"The authors have no conflicts of interest to declare that are relevant to the content of this article.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}}]}}